PLSE - Pulse Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.36
+0.39 (+3.21%)
As of 1:25PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close11.98
Open12.03
Bid12.27 x 1800
Ask12.45 x 1100
Day's Range12.03 - 12.58
52 Week Range8.60 - 23.48
Volume26,989
Avg. Volume70,830
Market Cap254.458M
Beta (3Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-2.22
Earnings DateMar 12, 2018 - Mar 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire21 hours ago

    Pulse Biosciences Announces Two Appointments Focused on CellFX™ Commercialization: Promotion of Edward Ebbers and Addition of Robert Tyson

    Pulse Biosciences, Inc. (PLSE), a medical technology company bringing to market its proprietary CellFX™ System, today announced the promotion of Edward Ebbers to Executive Vice President and General Manager, Dermatology, and the addition of Robert Tyson as Vice President of Sales, North America. The leadership pair brings more than 35 years of combined experience commercializing novel technologies in the aesthetic dermatology market and the necessary skillsets to launch and scale the CellFX System and its growing pipeline of applications into the aesthetic dermatology market.

  • Business Wire3 days ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 23,750 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on January 15, 2019.

  • Business Wire11 days ago

    Pulse Biosciences Announces Positive Clinical Results of Its Nano-Pulse Stimulation™ Technology Platform to Treat Patients with Sebaceous Hyperplasia Lesions on the Face

    Pulse Biosciences, Inc. (PLSE) today announced positive results from its clinical efficacy study using proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat patients with Sebaceous Hyperplasia (SH), a difficult-to-treat skin condition that typically presents on the face. Initial data indicate that 221 of 222 (99.5%) facial SH lesions treated with NPS energy were rated as clear or mostly clear by clinical investigators 60 days post treatment. NPS is a non-thermal technology that utilizes ultra-short, nanosecond energy pulses that directly interacts with the physical structure of cells without disrupting the integrity of non-cellular tissues.

  • How Many Insiders Bought Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
    Simply Wall St.24 days ago

    How Many Insiders Bought Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...

  • Business Wirelast month

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,500 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on December 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual’s entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wirelast month

    Pulse Biosciences, Inc. Announces Closing of Its $45 Million Rights Offering

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that its rights offering has closed. The rights offering resulted in the issuance of 3,581,148 shares of the Company’s common stock at a price of $12.5658 per share for total gross proceeds of $45 million to the Company. Investors who have participated in the rights offering should expect to see the shares issued to them in book-entry or, uncertificated, form.

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wirelast month

    Pulse Biosciences, Inc. Announces Oversubscription, Pricing and Preliminary Results for Its $45 Million Rights Offering

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced the completion of its rights offering, which expired at 5:00 p.m. Eastern Time on December 6, 2018 (the “Expiration Date”). In accordance with the pricing structure of the rights offering described in the prospectus relating to the offering, Pulse Biosciences has determined that the final subscription price per share for the shares offered in the rights offering is $12.5658 per share, which is the volume weighted average price of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.

  • Business Wire2 months ago

    Pulse Biosciences, Inc. Announces Commencement of Rights Offering

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has commenced its previously announced rights offering of $45,000,000 of its common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m. Eastern Time on Thursday December 6, 2018 (the “Expiration Date”). Pursuant to the rights offering, Pulse Biosciences is distributing, at no charge to the holders of its common stock, non-transferable subscription rights to purchase up to $45,000,000 of shares of its common stock at a subscription price per share equal to the lesser of (i) $13.33 per share (the “Initial Price”) or (ii) the volume weighted average price (the “Alternate Price”) of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.

  • Business Wire2 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on November 15, 2018.

  • Business Wire2 months ago

    Pulse Biosciences, Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of Its Registration Statement

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has set key dates and pricing structure for its previously announced rights offering of $45,000,000 of its common stock. Pulse Biosciences intends to issue non-transferable subscription rights to purchase shares of its common stock to common stockholders as of 5:00 p.m. Eastern Time on Monday November 19, 2018 (the “Record Date”).

  • Business Wire3 months ago

    Pulse Biosciences Quarterly Investor Conference Call

    Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

  • Business Wire3 months ago

    Pulse Biosciences Files Registration Statement for Rights Offering

    Pulse Biosciences, Inc. (PLSE) (the “Company”, or “Pulse Biosciences”) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001 per share, at a subscription price to be determined. Assuming the rights offering is fully subscribed, the Company will receive gross proceeds of approximately $45 million, less expenses of the rights offering.

  • Business Wire3 months ago

    Pulse Biosciences to Report Third Quarter 2018 and Operational Highlights and Financial Results

    Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, today announced that the Company will report third quarter 2018 operational highlights and financial results on Tuesday, October 30, 2018.

  • Business Wire3 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 20,750 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on October 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire3 months ago

    Pulse Biosciences Announces Continued Expansion of Its Clinical Study Programs in Dermatology

    Fourth Dermatology Study Will Evaluate Nano-Pulse Stimulation™ in Treating Cutaneous Warts

  • Simply Wall St.3 months ago

    What Kind Of Risk Should You Expect For Pulse Biosciences Inc (NASDAQ:PLSE)?

    Anyone researching Pulse Biosciences Inc (NASDAQ:PLSE) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...

  • Business Wire4 months ago

    Pulse Biosciences to Present at the Cantor Global Healthcare Conference

    Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that Darrin Uecker, President and Chief Executive Officer, is scheduled to present at the Cantor Global Healthcare Conference in New York at 4:00 p.m.

  • Business Wire4 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse StimulationTM (NPSTM) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 34,250 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 17, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire5 months ago

    Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders

    Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.

  • Business Wire6 months ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 18,250 shares of Pulse Biosciences common stock to five new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 3, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire6 months ago

    Pulse Biosciences Quarterly Investor Conference Call

    Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

  • ACCESSWIRE6 months ago

    Pulse Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Pulse Biosciences, Inc. (NASDAQ: PLSE ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern Time. ...

  • Business Wire6 months ago

    Pulse Biosciences Treats Initial Patient in Its Human Study Evaluating the Effects of Nano-Pulse Stimulation in Basal Cell Carcinoma

    Pulse Biosciences, Inc. (PLSE) today announced the treatment of the first patient in a clinical study to evaluate Nano-Pulse Stimulation (NPS) in a common skin cancer, Basal Cell Carcinoma (BCC). Patients in the study will be treated with NPS prior to resection of the BCC lesion, which is the standard of care for BCC lesions. Post resection tissue samples will be assessed for elimination of the BCC lesion in the NPS treatment zone and for biomarkers indicating an immune response to the NPS-treated BCC lesions.